Humira

Official Company Product Information

Official Company Warning Information

Other Information about Humira

Top

Source


	Relieves the pain that you have with RA			Slows down the rate at which your RA progresses
	Reduces the number of swollen and tender joints			Helps fight the fatigue that you experience with RA
	Proven to be safe and effective - HUMIRA is FDA approved			Works fast. Some patients have seen results as quickly as 1-2 weeks after the initial dose
	Increases your mobility			Convenient dosing, only once every two weeks
				Easy to inject using a pre-measured and pre-filled syringe


	HUMIRA is a TNF-α antagonist indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active RA who have had an inadequate response to one or more DMARDs. HUMIRA can be used alone or in combination with MTX or other DMARDs. TUBERCULOSIS (TB) AND INVASIVE OPPORTUNISTIC FUNGAL INFECTIONS HAVE BEEN OBSERVED IN PATIENTS TREATED WITH TNF-BLOCKING AGENTS, INCLUDING HUMIRA. PATIENTS SHOULD BE EVALUATED FOR LATENT (INACTIVE) TB WITH A SKIN TEST. TREATMENT OF TB SHOULD BE INITIATED PRIOR TO THERAPY WITH HUMIRA. THE BENEFITS AND RISKS OF HUMIRA SHOULD BE CAREFULLY CONSIDERED BEFORE INITIATION OF TREATMENT FOR PATIENTS WHO HAVE RESIDED IN REGIONS WHERE TB OR HISTOPLASMOSIS IS ENDEMIC. SERIOUS INFECTIONS AND SEPSIS, INCLUDING FATALITIES, HAVE BEEN REPORTED WITH THE USE OF TNF-BLOCKING AGENTS, INCLUDING HUMIRA. MANY OF THESE INFECTIONS OCCURRED IN PATIENTS PREDISPOSED TO INFECTIONS BECAUSE OF CONCOMITANT IMMUNOSUPPRESSIVE THERAPY IN ADDITION TO THEIR UNDERLYING DISEASE. PATIENTS WHO DEVELOP A NEW INFECTION WHILE USING HUMIRA SHOULD BE MONITORED CLOSELY. TREATMENT SHOULD BE DISCONTINUED IF A PATIENT DEVELOPS A SERIOUS INFECTION. DO NOT START HUMIRA IN PATIENTS WITH ACTIVE INFECTION (INCLUDING CHRONIC OR LOCALIZED), OR ALLERGY TO HUMIRA OR ITS COMPONENTS. EXERCISE CAUTION IN PATIENTS WITH A HISTORY OF RECURRENT INFECTION OR WITH UNDERLYING CONDITIONS, WHICH MAY PREDISPOSE PATIENTS TO INFECTIONS. TNF-blocking agents, including HUMIRA, have been associated in rare cases with exacerbation of demyelinating disease. Exercise caution when considering HUMIRA for patients with these disorders. Lymphoma has been observed in patients treated with TNF-blocking agents. The role of TNF-blocking agents in the development of malignancy is not known. 02L-640-5380-3

Source

Return To Top

Table Of Contents	Relief Of Arthritis Pain	Relief Of The Pain Of Fibromyalgia
Write To Karl Loren -- He Pledges To Answer EVERY Personal Message, Personally. Click here or on his name in the box below.

I promise to answer your message -- click here to send me a personal message

Dear Karl,

You can reach Karl Loren at www.PainStudy.com by mail at 1831 N. Bel Aire Drive, Burbank, CA 91504. Within the US and Canada, use the toll free number: (800) 523-4521, the local number: (818) 558-1799, the FAX: (818) 558-7299, eMail to karl@painstudy.com

Copyright © May 20, 2008 6:26 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED. Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions: One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site. This permission does not extend to materials on this site which are copyrighted by others.